Figure 3.

Evaluation of SRBAL therapy. (A) Survival curves of all five conditions. Survival rate and median survival time (MST) of monkeys treated with SRBAL were improved in group A (100%, MST = 336 h, p < 0.001), group B (50%, MST = 248 h, p < 0.001) and group C (17%, MST = 131.5 h, p < 0.001) compared to those of the two control groups, sham (0%, MST = 90 h) and ALF (0%, MST = 60.5 h). (B) IgM and (C) IgG antibody levels in monkey blood before and after SRBAL treatments. (D)Electrophoresis results of the PERV DNA extracted from porcine hepatocytes and monkey PBMCs.Sample 1, 3, 5: porcine liver; Sample 2, 4, 6: rhesus monkey blood. (E) Droplet digitalPCR(ddPCR) results of the PERV DNA from porcine hepatocytes and monkey PBMCs and liver. Sample 1: pig liver; Sample 2, 3: monkey liver; Sample 4, 5: monkey blood. (F)RT-PCR results of the PERV mRNA extracted from porcine hepatocytes and monkey PBMCs. (G)Hematological parameters including red blood cell (RBC), hemoglobin (HGB), platelet (PLT) and prothrombin time (PT). (H)Biochemical parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TB), ammonia, blood urea nitrogen (BUN) and S-100 β. ◇p < 0.05 groupsA, B, C versus ALF control group; *p < 0.05 sham group,groupsA, B, C versus ALF control group; ▽p < 0.05 sham group, group A versus ALF control group; &p < 0.05 group A versus ALF control group; #p < 0.05 groupsA, B versus ALF